retatrutide phase 2 results obesity nejm 2023 (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive + osteoarthritis data we've ever seen in the 3 TRIUMPH-4 trial: Retatrutide Phase 2 NEJM Trial:

Ethics declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Independent Institutional Ethics Committee of IRCCS MultiMedica, Milan (protocol code 24/2012(153))

Estrogen helps regulate metabolism, appetite, and fat distribution

Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022

Purity: 99% (HPLC verified)

Mounjaro, or tirzepatide, stands out due to its unique dual-action mechanism that activates both GLP-1 and GIP receptors

15 Studies have indicated that GLP-1R KO mice exhibit greater numbers of osteoclasts and greater bone resorption than wild-type controls